相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results
Andrew Spencer et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes
P. Hari et al.
LEUKEMIA (2017)
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Michel Attal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Update on the optimal use of bortezomib in the treatment of multiple myeloma
Meera Mohan et al.
CANCER MANAGEMENT AND RESEARCH (2017)
Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study
Meletios A. Dimopoulos et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Marizomib for central nervous system-multiple myeloma
Ashraf Badros et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1
P. G. Richardson et al.
BLOOD (2016)
Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM
Andrzej Jakubowiak et al.
BLOOD (2016)
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
Meletios A. Dimopoulos et al.
LANCET ONCOLOGY (2016)
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
P. Moreau et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial
Jesus F. San-Miguel et al.
LANCET HAEMATOLOGY (2016)
Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma
Jatin J. Shah et al.
BLOOD (2015)
Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study
Philippe Moreau et al.
HAEMATOLOGICA (2015)
Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study
Philippe Moreau et al.
HAEMATOLOGICA (2015)
Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma
Pieter Sonneveld et al.
BLOOD (2015)
Curing myeloma at last: defining criteria and providing the evidence
Bart Barlogie et al.
BLOOD (2014)
Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma
Shaji K. Kumar et al.
BLOOD (2014)
Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients
Paul G. Richardson et al.
BLOOD (2014)
Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved Survival
Antonio Palumbo et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study
Shaji K. Kumar et al.
LANCET ONCOLOGY (2014)
An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma
Massimo Offidani et al.
OncoTargets and Therapy (2014)
Phase Ib Dose-Escalation Study (PX-171-006) of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Progressive Multiple Myeloma
Ruben Niesvizky et al.
CLINICAL CANCER RESEARCH (2013)
Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study
Meletios Dimopoulos et al.
LANCET ONCOLOGY (2013)
Aphase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
David S. Siegel et al.
BLOOD (2012)
A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma
Andrzej J. Jakubowiak et al.
BLOOD (2012)
Design and rationale of FOCUS (PX-171-011): A randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM)
Roman Hajek et al.
BMC CANCER (2012)
Superiority of the Triple Combination of Bortezomib-Thalidomide-Dexamethasone Over the Dual Combination of Thalidomide-Dexamethasone in Patients With Multiple Myeloma Progressing or Relapsing After Autologous Transplantation: The MMVAR/IFM 2005-04 Randomized Phase III Trial From the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation
Laurent Garderet et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/GMMG-HD4 Trial
Pieter Sonneveld et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Molecular Mechanisms of Acquired Proteasome Inhibitor Resistance
Andrew J. Kale et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Pharmacokinetics, Pharmacodynamics, Metabolism, Distribution, and Excretion of Carfilzomib in Rats
Jinfu Yang et al.
DRUG METABOLISM AND DISPOSITION (2011)
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
Philippe Moreau et al.
LANCET ONCOLOGY (2011)
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients
Sara Bringhen et al.
BLOOD (2010)
Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer
Erik Kupperman et al.
CANCER RESEARCH (2010)
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study
Michele Cavo et al.
LANCET (2010)
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial
Maria-Victoria Mateos et al.
LANCET ONCOLOGY (2010)
Infections in Patients with Multiple Myeloma in the Era of High-Dose Therapy and Novel Agents
Marcio Nucci et al.
CLINICAL INFECTIOUS DISEASES (2009)
Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma
Sundar Jagannath et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study
Asher Chanan-Khan et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
Jesus F. San Miguel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myelorna
Deborah J. Kuhn et al.
BLOOD (2007)
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma:: Combination therapy improves time to progression
Robert Z. Orlowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Impact of prior thalidomide (T) therapy on the efficacy of pegylated liposomal doxorubicin (PLD) and bortezomib (B) in relapsed/refractory multiple myeloma (RRMM)
P. Sonneveld et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials
S. Jagannath et al.
LEUKEMIA (2007)
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib
Paul G. Richardson et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma - Final time-to-event results from the SUMMIT trial
PG Richardson et al.
CANCER (2006)
Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma
S Lonial et al.
BLOOD (2005)
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Proteasome inhibition as a novel therapeutic target in human cancer
SV Rajkumar et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
A phase 2 study of bortezomib in relapsed, refractory myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Catalytic activities of the 20 S proteasome, a multicatalytic proteinase complex
M Orlowski et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2000)